Comparison of Two Dementia Care Interventions and Usual Care on Days Spent at Home: The D‐ CARE Randomized Clinical Trial
BACKGROUND: Days spent at home (DSAH) is a clinically meaningful patient-centered outcome among persons living with dementia (PLWD). OBJECTIVE: To evaluate whether either of two dementia care interventions increased the number of DSAH compared with each other and with usual care. DESIGN: Pragmatic 18-month 3-arm randomized clinical trial conducted from June 2019 through August 2023. SETTING: Four clinical trial sites in North Carolina, Texas, and Pennsylvania. PARTICIPANTS: Total of 1968 (90.4% of 2176) community-living PLWD with complete Medicare data. INTERVENTIONS: Health-system dementia care (HSDC) co-management by advance practice providers, community-based dementia care (CBDC) provided telephonically by a social worker, nurse, or licensed therapist, and usual care (UC), each lasting up to 18 months. MAIN OUTCOME: The number of DSAH was calculated as 546 (i.e., 18 months) minus the number of overnight days in a health care facility and days not alive, using data from Medicare. RESULTS: The percentages of DSAH were 83.5, 84.9, and 83.6 for the HSDC, CBDC, and UC groups, respectively. For each pairwise comparison among the three groups, incidence rate ratios for DSAH approximated 1.0, denoting no differences, and the corresponding mean differences in DSAH were small and not statistically significant: -7.2 (98.3% CI: -31.4 to 17.0) for HSDC versus CBDC; -0.3 (-48.4 to 47.7) for HSDC versus UC; and 6.9 (-41.3 to 55.5) for CBDC versus UC. There were no substantive differences in mean values across the three groups for days in any of the health care facilities. Mean [SD] days not alive were greatest for UC (68.3 [134.4]), followed by HSDC (65.3 [133.3]) and CBDC (60.0 [129.8]). CONCLUSIONS: In this pragmatic randomized clinical trial of dementia care programs, health system-based and community-based interventions did not differ from each other or from usual care in the number of DSAH for PLWD over the 18-month intervention period. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT03786471.
Authors
- Katy L. B. Araujo
- Maya L. Lichtenstein (ORCID: https://orcid.org/0000-0001-6270-575X)
- Rebecca V. Galloway (ORCID: https://orcid.org/0000-0002-8013-7781)
- David B. Reuben (ORCID: https://orcid.org/0000-0002-1363-4745)
- Elena Volpi (ORCID: https://orcid.org/0000-0001-8776-0384)
- Thomas M. Gill (ORCID: https://orcid.org/0000-0002-6450-0368)
- Peter N. Peduzzi (ORCID: https://orcid.org/0000-0002-7634-6804)
- Jodi Liu (ORCID: https://orcid.org/0000-0001-8076-3777)
- Alan B. Stevens (ORCID: https://orcid.org/0000-0003-2247-1228)
- Jeff D. Williamson (ORCID: https://orcid.org/0000-0002-0185-5823)
- Jenny Summapund
- Mia Yang (ORCID: https://orcid.org/0000-0002-5439-3706)
- Lee A. Jennings (ORCID: https://orcid.org/0000-0002-9524-6921)
- Erich J. Greene (ORCID: https://orcid.org/0000-0002-9473-830X)
- Yunshan Xu (ORCID: https://orcid.org/0009-0009-6679-0512)
Institutions
- University of Southern California (US)
- Atrium Health Wake Forest Baptist (US)
- University of California, Los Angeles (US)
- Yale University (US)
- Geisinger Wyoming Valley Medical Center (US)
- Baylor Scott & White Health (US)
- University of Oklahoma Health Sciences Center (US)
- Geisinger Health System (US)
- The University of Texas Medical Branch at Galveston (US)
Publication Details
- Journal
- Journal of the American Geriatrics Society
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1111/jgs.70838
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00